OptimizeRx Enables Healthcare Providers to Adapt to COVID-19 with New Telehealth Capabilities
2020年4月22日 - 9:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies, payers and providers,
is helping healthcare clients to quickly shift from onsite to
remote care management via telehealth in response to the COVID-19
pandemic.
For several years, the Israel-based O2 Center
of Cardiac Rehabilitation has been using OptimizeRx’s
RMDY digital health tools alongside its onsite rehabilitation
services. O2 cardiac rehabilitation patients are given daily tasks
via the RMDY mobile app to report symptoms and biometrics, and
complete questionnaires.
The O2 care team supervises the patients using RMDY’s care
management dashboard and intervenes when needed using chat and
video. Since the closure of O2’s clinic two weeks ago due to social
distancing guidelines, the O2 team has onboarded many new patients
to the RMDY platform to help manage their condition remotely.
Otherwise, they would not be able to receive appropriate care from
their medical team.
“We’re glad we can help patients get and stay healthy using our
digital health tools when they are unable to see their healthcare
providers in person,” said Miriam Paramore, president of
OptimizeRx. “One of the primary reasons we acquired RMDY in late
2019 was because we saw that the tipping point for virtual care and
telehealth was on the horizon. No one could have anticipated that a
pandemic like COVID-19 would bring about this change so quickly.
Thankfully, our tools make it easy for clients to transition from
onsite to virtual care.”
Telem, a provider of mental health services for teenagers, is
another OptimizeRx client making use of the RMDY platform to
provide services digitally. Like O2, due to the COVID-19 social
distancing codes, Telem had to shift quickly to providing care for
their patients remotely, making their services available to
patients who otherwise wouldn’t have access to them. OptimizeRx’s
RMDY platform enabled Telem to onboard more than 1,700 additional
patients to digital behavioral support, self-assessment and
monitoring.
According to William Febbo, CEO of OptimizeRx: “The driving
force behind our digital communication platform is how we can
uniquely bridge the gap between people who need care and those who
provide it. In a digital world, and especially during a crisis like
COVID-19, we need digital health tools that work for all those
focused on delivering solutions for care management, adherence and
affordability. Our continued investment in RMDY technology and its
commercial team provides the basis for another very large market
opportunity for OptimizeRx.”
The OptimizeRx network currently reaches more than 60% of U.S.
ambulatory point-of-care providers, delivering therapeutic support
and patient financial assistance through leading EHR platforms that
include Allscripts, Amazing Charts, NextGen and NewCrop.
About OptimizeRx®OptimizeRx
Corporation (NASDAQ: OPRX) is a digital health company that
facilitates communication at point-of-care among all stakeholders
in healthcare. Primarily focused on life science and payer clients,
its suite of digital and mobile SaaS-based solutions enables
affordability, patient adherence and care management. OptimizeRx’s
network reaches more than 60% of U.S. ambulatory providers,
delivering therapeutic support on specialty medications and patient
financial assistance directly within a provider’s workflow through
leading electronic health platforms OptimizeRx’s fully integrated
platform ensures the real-time exchange of information—connecting
care to improve provider knowledge, patient engagement and
ultimately healthier outcomes.
For more information, go to OptimizeRx.com, and follow the
company on Twitter and LinkedIn.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker, CFOTel (248)
651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira Alejandra, Media
Relations ManagerTel (754) 245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both, CMATel
(949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024